摘要 |
The present invention provides compositions and methods for the treatment of herpes virus infections. In one aspect, the invention provides a combination therapy for treating a herpes virus infection comprising the administration to a subject of an anti-herpes virus agent in combination with a cyclooxygenase-2 selective inhibitor. In another aspect, the invention provides a mono therapy for treating a herpes virus infection comprising administering a cyclooxygenase-2 selective inhibitor to a subject. Preferably, the cyclooxygenase-2 selective inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, lumiracoxib, etoricoxib, parecoxib, 2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methylbutoxy)-5-`4-(methylsulphonyl) phenyl!-3(2H)-pyridazinone, and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid; and the anti-herpes virus agent selected from the group consisting of ganciclovir, foscarnet, cidofovir, acycloguanosine, tri-fluorothymidine, acyclovir, famciclovir, and valaciclovir. |